MedTrace Logo

A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

NCT04660617 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-05-11

No results posted yet for this study

Summary

The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Conditions

  • Prostate Cancer Metastatic

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Hao Zeng, Dr. · West China Hospital

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-11-01
Completion
2023-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04660617 on ClinicalTrials.gov